Antiretroviral treatment in 1998

Lancet

Volumn 352, Issue 9144, 1998, Pages 1919-1922

  Montaner, Julio S G ^a   Hogg, Robert ^a   Raboud, Janet ^a   Harrigan, Richard ^a   O'Shaughnessy, Michael ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SHORT SURVEY; VIRUS LOAD; VIRUS REPLICATION;

EID: 0032512320     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07532-1     Document Type: Review

References (55)

1. 1 Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-70.
2. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-54.
3. 3 Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-39.
4. 4 Montaner JSG, Reiss P, Cooper D, et al. A randomised, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV infected patients: the INCAS trial. JAMA 1998; 279: 930-37.
5. 5 Gerstoft J, on behalf of the AVANTI Group. AVANTI 2: a randomised, double-blind, comparative trial to evaluate the efficacy, safety and tolerance of combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC vs AZT/3TC/indinavir in antiretroviral naïve patients. In: Proceedings of the International Congress on Antimicrobial Agents and Chemotherapy; September 1997, Toronto (abstr 1-87).
6. 6 Clumeck N, for the AVANTI Study Group. AVANTI 3: a randomised, double-blind, comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs AZT/3TC/nelfinavir in antiretroviral naïve patients. In: Proceedings of the 5th Conference on Retroviruses and Opportunistic Infections; February 1998, Chicago, IL (abstr 8).
7. 7 Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of the international panel. JAMA 1996; 276: 146-54.
8. 8 Hogg RS, O'Shaughnessy MV, Gataric N, Craib K, Schechter MT, Montaner JSG. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349: 1294.
9. 9 Hogg RS, Health KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-54.
10. 10 Rhone SA, Hogg RS, Yip B, et al. Do dual nucleoside regimens have a role in the era of viral load driven antiretroviral therapy? J Infect Dis 1998; 178: 662-68.
11. 11 Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997 - an update. JAMA 1997; 277: 1962-69.
12. + T cell recovery in a large cohort treated with highly active antiretroviral therapy at advanced stages of HIV disease. In: Proceedings of the World AIDS Conference; June 28-July 3, 1998, Geneva (abstr 41179).
13. 13 Sekaly RP, Ringuette N, Lacaille J, et al. Rapid reconstruction of the T cell repertoire (TCR) following antiretroviral treatment during primary HIV infection. In: Proceedings of the 12th World AIDS Conference; June 28-July 3, 1998, Geneva (abstr 12185).
14. 14 Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33.
15. 15 Pallela FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
16. 16 Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir AIDS 1998; 12: F9-F14.
17. 17 Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy. AIDS 1998; 12: 1619-24.
18. 18 Montaner JSG, Montessori V, Raboud JM, et al. How low is low enough: suppression of plasma viral load below 20 copies/mL is necessary for long term virological response. In: Proceedings of the 12th World AIDS conference; June 28-July 3, 1998, Geneva (abstr 12364).
19. 19 Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998 - updated recommendations of the International AIDS Society. JAMA 1998; 280: 78-86.
20. 20 Kaufmann D, Pantaleo G, Sudre P, Talenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351: 723-24.
21. 21 Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-91.
22. 22 CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413-21.
23. 23 Womg JK, Hezareh M, Gunthard H, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-95.
24. 24 Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-300.
25. 25 Chun T, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94: 13193-97.
26. 26 Montaner JSG, Harris M, Mo T, Harrigan PR. Rebound of plasma viral load following prolonged suppression with combination therapy. AIDS 1998; 12: 1398-99.
27. 27 Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997; 387: 188-91.
28. 28 Montaner JSG, Raboud JM, Rae S, for the INCAS and AVANTI Study Groups. Adherence to treatment increases duration of virological suppression regardless of pVL nadir. In: Proceedings of the 38th Interscience Conference on Antomicrobial Agents and Chemotherapy; September 1998, San Diego, CA (abstr 191).
29. 29 Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
30. 30 Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-83.
31. 31 Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100 week follow-up. JAMA 1998; 280: 35-41.
32. 32 De Wolf F, Weverling GJ, Lukashov W, et al. Alternative multidrug regiman provides improved suppression of HIV-1 replication over triple therapy. In: Proceedings of the 12th World AIDS Conference; June 18-July 3, 1998, Geneva (abstr 11156).
33. 33 Chesney M, Ickovics J, for the Recruitment, Adherence and Retention Committee of the ACTG (1997). Adherence to combination therapy in AIDS clinical trials (1997). Paper presented at the Annual Meeting of the AIDS Clinical Trials Group; July 22, 1997, Washington, DC.
34. 34 Altice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med 1998; 129: 503-05.
35. 35 Montaner JSG, Raboud JM, Rae S, for the INCAS and AVANTI study groups. How early can we predict 52 week virologic success in antiretroviral naïve patients. AIDS 1998; 12: S15 (abstr).
36. 36 Borleffs JC, the CHEESE Study Team. First comparative study of saquinavir soft gel capsules vs indinavir as part of triple therapy regiman (CHEESE). In: Programme and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998, Chicago, IL (abstr 387b).
37. 37 Staszewski S, Morales-Ramirez J, Flanigan T, et al. A phase II, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV)+indinavir (IDV), versus EFV+zidovudine (ZDV)+lamivudine (3TC). versus IDV+ZDV+3TC at 24 weeks [DMP 266-006]. In: Proceedings of the World AIDS Conference; June 28-July 3, 1998, Geneva (abstr 22336).
38. 38 Fischl M, Greenberg S, Clumeck N, et al. Safety and activity of abacavir (1592, ABC) with 3TC/ZDV in antiretroviral naïve subjects. In: Proceedings of the 12th World AIDS Conference; June 28-July 3, 1998, Geneva (abstr 127/12230).
39. 39 Shaefer M, Eron J, Yetzer E, et al. Combivir (Lamivudine (3TC) 150 mg/Zidovudine (ZDV) 300 mg) given BID plus a protease inhibitor (PI) compared to 3TC 150 mg BID and ZDV 200 mg TID plus a PI. In: Proceedings of the 12th World AIDS Conference; June 28-July 3, 1998, Geneva (abstr 12220).
40. 40 Johnson M, Petersen A, Winslade J, Clendeninn N. Comparison of bid and tid dosing of Viracept in combination with stavudine and lamivudine. In: Programme and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5. 1998, Chicago, IL (abstr 373).
41. 41 Sension M, Elion R, Farthing C, et al. Open label pilot studies to assess the safety and efficacy of bid dosing regimens of Viracept combined with MRTIs in HIV-infected treatment naïve patients. In: Programme and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998, Chicago, IL (abstr 1-105).
42. 42 Ferthing C, Norris D, Slater L, et al. Fortovase Soft Gel Capsule BID Regimens in Combination with 2 Nucleosides or Nelfavir Plus 1 Nucleoside in HIV-1 Infected Patients. Proceeding of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1998, San Diego, CA (abstr I-105).
43. 43 Cameron DW, Japour A, Mellors J, et al. Antiretroviral safety and durability of ritonavir-saquinavir in protease inhibitor-naïve patients in year two of follow-up. In: Programme and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998. Chicago, IK (abstr 338)
44. 44 Harberl A, Gute P, Carlebach S, et al. Once-daily therapy (NVP/ddI/3TC_ for the IVUD HIV-1 infected population of the Frankfurt HIV-Cohort. In: Proceedings of the 12th World AIDS Conference; June 28-July 3, 1998, Geneva (abstr 22398).
45. 45 Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effects in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537-45.
46. 46 Harris M, Durakovic C, Rae S, et al. Apilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. J Infect Dis 1998; 177: 1514-20.
47. 47 Winslow D, Myers A, Blick G, et al. A phase II randomized open label study of adefovir dipivoxil (Preveon(tm), ADV) in combinations with indinavir (IDV), ziodovudine (ZDV), lamivudine (3TC), and stavudine (D4T) in therapy naïve HIV-infected patients. In: Proceedings of the 12th World AIDS Conference; June 28-July 3, 1998, Geneva (abstr 22371).
48. 48 Montaner JSG, Shillington A, Gonzalez Montaner LJ. HIV/AIDS treatment - lessons fron the tuberculosis experience. Drug Resist Updates 1998 (in press).
49. 49 Harrigan PR, Montaner JS, Hogg RS, et al. Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a community setting. In: Proceedings of the 2nd International Workshop on HIV Drug Resistance & Treatment Strategies; June 24-27, 1998, Lake Maggiore, Italy (abstr 55).
50. 50 Zolopa AR, Shafer R, Warford A, Montoya J, Katzenstein D, Merigan T. HIV genotypic predictors of antiretroviral response to saquinavir (SQV)/ritonavir (RTV) therapy in patients who have failed prior protease inhibitors (PIs): a clinical cohort study. In: Proceedings of the 12th World AIDS Conference; June 28-July 3, 1998, Geneva 57 (abstr 32390).
51. 51 Patrick AK, Zhang M, Hertogs K, et al. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program. In: Proceedings of the 2nd International Workshop on HIV Drug Resistance & Treatment Strategies; June 24-27, 1998, Lake Maggiore, Italy (abstr 57).
52. 52 Pauwels R, Hertogs K, Kemp S, et al. Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic assays with correlative data analysis. In: Proceedings of the 2nd International Workshop on HIV Drug Resistance & Treatment Strategies; June 24-27, 1998, Lake Maggiore, Italy (abstr 51).
53. 53 Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 1998; 279: 1984-91.
54. 54 Hogg RS, Craib KJP, Weber A, et al. One world, one hope: the cost of making antiretroviral therapy available to all nations. AIDS 1998 (in press).
55. 55 AIDS, the unbridgable gap. Lancet 1998; 351: 1825.